|

INCB123667 Clinical Trials

2 actively recruiting trials across 2 locations

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

  • Incyte Corporation2

Indications

  • Ovarian Cancer2
  • Cancer2

Mobile, Alabama1 trial

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Usa Health Mitchell Cancer Institute

Phase 2

Duarte, California1 trial

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

City of Hope Medical Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.